Department of Biomedical Engineering, Changzhi Medical College, Changzhi, 046013, Shanxi, China.
International Medical Campus, Iran University of Medical Sciences, Tehran, Iran.
Ann Clin Microbiol Antimicrob. 2022 Aug 17;21(1):37. doi: 10.1186/s12941-022-00529-z.
Methicillin-resistant Staphylococcus aureus (MRSA) infections are considered an important public health problem, and treatment options are limited. Accordingly, in this meta-analysis, we analyzed published studies to survey in vitro activity of recently approved antibiotics against MRSA isolates.
We searched electronic databases; PubMed, Scopus, and Web of Science to identify relevant studies (until November 30, 2020) that have focused on the in vitro activity of telavancin, dalbavancin, oritavancin, and tedizolid against MRSA isolates. Statistical analyses were conducted using STATA software (version 14.0).
Thirty-eight studies were included in this meta-analysis. Overall in vitro activity of tedizolid on 12,204 MRSA isolates was 0.250 and 0.5 µg/mL for MIC and MIC, (minimum inhibitory concentration at which 50% and 90% of isolates were inhibited, respectively), respectively. The overall antibacterial activity of dalbavancin on 28539 MRSA isolates was 0.060 and 0.120 µg/mL for MIC and MIC, respectively. The overall antibacterial activity of oritavancin on 420 MRSA isolates was 0.045 and 0.120 µg/mL for MIC and MIC, respectively. The overall antibacterial activity of telavancin on 7353 MRSA isolates was 0.032 and 0.060 µg/mL for MIC and MIC, respectively. The pooled prevalence of tedizolid, telavancin, and dalbavancin susceptibility was 100% (95% CI: 100-100).
Telavancin, dalbavancin, oritavancin, and tedizolid had potent in vitro activity against MRSA isolates. The low MICs and high susceptibility rates of these antibiotics recommend a hopeful direction to introduce useful antibiotics in treating MRSA infections in the future.
耐甲氧西林金黄色葡萄球菌（MRSA）感染被认为是一个重要的公共卫生问题，治疗选择有限。因此，在这项荟萃分析中，我们分析了已发表的研究，以调查最近批准的抗生素对 MRSA 分离株的体外活性。
我们检索了电子数据库；PubMed、Scopus 和 Web of Science，以确定（截至 2020 年 11 月 30 日）专注于替拉万星、达巴万星、奥利万星和替加环素对 MRSA 分离株体外活性的相关研究。使用 STATA 软件（版本 14.0）进行统计分析。
这项荟萃分析共纳入 38 项研究。替加环素对 12204 株 MRSA 分离株的总体体外活性分别为 MIC 和 MIC 的 0.250 和 0.5µg/mL（分别为最小抑菌浓度，50%和 90%的分离株被抑制）。达巴万星对 28539 株 MRSA 分离株的总体抗菌活性分别为 MIC 和 MIC 的 0.060 和 0.120µg/mL。奥利万星对 420 株 MRSA 分离株的总体抗菌活性分别为 MIC 和 MIC 的 0.045 和 0.120µg/mL。替拉万星对 7353 株 MRSA 分离株的总体抗菌活性分别为 MIC 和 MIC 的 0.032 和 0.060µg/mL。替加环素、替拉万星和达巴万星的敏感性总体流行率为 100%（95%CI：100-100）。
替拉万星、达巴万星、奥利万星和替加环素对 MRSA 分离株具有强大的体外活性。这些抗生素的 MIC 较低，敏感性较高，这为未来治疗 MRSA 感染引入有用的抗生素指明了一个有希望的方向。
Zotero 插件